We are a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system in order to tackle cancer and inflammation. Since our founding in 2007, our goal has been to develop a diverse and unique pipeline rooted in high quality science and innovation. Faron is focused on mastering immune modulation by harnessing endothelial receptors to control and mediate immune responses.
| CEO: |
Juho Jalkanen |
| CFO: |
Jurriaan Dekkers |
| Chairman: |
Tuomo Pätsi |
| Chief Technology Officer: |
Heikki Jouttijärvi |
| Independent Non-Executive Director: |
John Poulos |
| Non-Executive Director: |
Markku Jalkanen, Marie-Louise Fjällskog, Christine Roth , Colin Bond , George Stanley Golumbeski |
| Address: |
Joukahaisenkatu 6, Turku, Finland |
| Phone: |
+358 2 469 5151 |
| Fax: |
+358 2 469 5152 |
| Website: |
http://www.faronpharmaceuticals.com |
| Email: |
|